Display options
Share it on

MAbs. 2019 Jan;11(1):129-144. doi: 10.1080/19420862.2018.1530920. Epub 2018 Oct 19.

Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab.

mAbs

Nayoung Lee, JongAh Joanne Lee, Hahymn Yang, Serim Baek, Soohwan Kim, Sooshin Kim, Tongkeun Lee, Dami Song, Gwangmin Park

Affiliations

  1. a Analytical Method Development Team , Samsung Bioepis Co., Ltd ., Incheon , South Korea.
  2. b Bioanalysis Team , Samsung Bioepis Co., Ltd ., Incheon , South Korea.

PMID: 30296198 PMCID: PMC6343792 DOI: 10.1080/19420862.2018.1530920

Abstract

Biosimilars are biologic products that are highly similar to a licensed reference product in terms of quality, safety, and efficacy. SB5 is a biosimilar of Humira® (adalimumab) developed by Samsung Bioepis. To demonstrate its biosimilarity in quality to Humira®, we performed a comprehensive characterization in terms of structure, physicochemical properties, and biological properties following the International Conference on Harmonization, US Food and Drug Administration, and European Medicines Agency guidelines. We analyzed all available batches of SB5 and more than 100 EU- and US-sourced lots of Humira® using state-of-the-art methods whenever possible, and compared the two sets of data. The structural properties comprised primary and higher-order structures and N-glycosylation. The physicochemical characteristics were categorized into liquid chromatographic patterns and electrophoretic pattern concerning size and charge heterogeneity. The biological properties were examined by in vitro functional assays. Overall, SB5 and Humira® were shown to be similar to each other in terms of quality attributes. For some of the quality attributes, minor differences were observed. However, the observed differences have been adequately addressed and demonstrated these do not translate into clinically meaningful differences in terms of safety, purity, and potency.

Keywords: Hadlima; Imraldi; SB5; adalimumab; biosimilar; characterization; critical quality attribute

References

  1. J Pharm Sci. 2011 Jun;100(6):2071-86 - PubMed
  2. MAbs. 2015;7(5):805-11 - PubMed
  3. Nat Biotechnol. 2011 Aug 05;29(8):690-3 - PubMed
  4. MAbs. 2012 Jan-Feb;4(1):17-23 - PubMed
  5. Pharmacol Ther. 2008 Feb;117(2):244-79 - PubMed
  6. MAbs. 2016 Aug-Sep;8(6):1088-97 - PubMed
  7. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):250-6 - PubMed
  8. Curr Opin Immunol. 2008 Aug;20(4):471-8 - PubMed
  9. Mol Immunol. 2007 Mar;44(7):1524-34 - PubMed
  10. BioDrugs. 2016 Aug;30(4):321-38 - PubMed
  11. J Clin Pharm Ther. 2017 Dec;42(6):672-678 - PubMed
  12. MAbs. 2011 Nov-Dec;3(6):577-83 - PubMed
  13. Arthritis Rheumatol. 2018 Jun;70(6):832-840 - PubMed
  14. MAbs. 2010 Nov-Dec;2(6):613-24 - PubMed
  15. Nat Rev Immunol. 2010 May;10(5):345-52 - PubMed
  16. MAbs. 2017 Jan;9(1):127-139 - PubMed
  17. Nat Biotechnol. 2011 Apr;29(4):310-2 - PubMed
  18. Physiol Rev. 1995 Jul;75(3):591-609 - PubMed
  19. J Pharm Sci. 2011 Nov;100(11):4642-54 - PubMed

Substances

MeSH terms

Publication Types